Binding of sulphonylureas to plasma proteins - A KATP channel perspective.

Sulphonylurea drugs stimulate insulin secretion from pancreatic β-cells primarily by inhibiting ATP sensitive potassium (KATP) channels in the β-cell membrane. The effective sulphonylurea concentration at its site of action is significantly attenuated by binding to serum albumin, which makes it diff...

Full description

Bibliographic Details
Main Authors: Peter Proks, Holger Kramer, Elizabeth Haythorne, Frances M Ashcroft
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5957440?pdf=render
_version_ 1817969447323828224
author Peter Proks
Holger Kramer
Elizabeth Haythorne
Frances M Ashcroft
author_facet Peter Proks
Holger Kramer
Elizabeth Haythorne
Frances M Ashcroft
author_sort Peter Proks
collection DOAJ
description Sulphonylurea drugs stimulate insulin secretion from pancreatic β-cells primarily by inhibiting ATP sensitive potassium (KATP) channels in the β-cell membrane. The effective sulphonylurea concentration at its site of action is significantly attenuated by binding to serum albumin, which makes it difficult to compare in vitro and in vivo data. We therefore measured the ability of gliclazide and glibenclamide to inhibit KATP channels and stimulate insulin secretion in the presence of serum albumin. We used this data, together with estimates of free drug concentrations from binding studies, to predict the extent of sulphonylurea inhibition of KATP channels at therapeutic concentrations in vivo. KATP currents from mouse pancreatic β-cells and Xenopus oocytes were measured using the patch-clamp technique. Gliclazide and glibenclamide binding to human plasma were determined in spiked plasma samples using an ultrafiltration-mass spectrometry approach. Bovine serum albumin (60g/l) produced a mild, non-significant reduction of gliclazide block of KATP currents in pancreatic β-cells and Xenopus oocytes. In contrast, glibenclamide inhibition of recombinant KATP channels was dramatically suppressed by albumin (predicted free drug concentration <0.1%). Insulin secretion was also reduced. Free concentrations of gliclazide and glibenclamide in the presence of human plasma measured in binding experiments were 15% and 0.05%, respectively. Our data suggest the free concentration of glibenclamide in plasma is too low to account for the drug's therapeutic effect. In contrast, the free gliclazide concentration in plasma is high enough to close KATP channels and stimulate insulin secretion.
first_indexed 2024-04-13T20:21:22Z
format Article
id doaj.art-a9c9cead1ead4bc3bde42dea0f80e156
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-04-13T20:21:22Z
publishDate 2018-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-a9c9cead1ead4bc3bde42dea0f80e1562022-12-22T02:31:32ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01135e019763410.1371/journal.pone.0197634Binding of sulphonylureas to plasma proteins - A KATP channel perspective.Peter ProksHolger KramerElizabeth HaythorneFrances M AshcroftSulphonylurea drugs stimulate insulin secretion from pancreatic β-cells primarily by inhibiting ATP sensitive potassium (KATP) channels in the β-cell membrane. The effective sulphonylurea concentration at its site of action is significantly attenuated by binding to serum albumin, which makes it difficult to compare in vitro and in vivo data. We therefore measured the ability of gliclazide and glibenclamide to inhibit KATP channels and stimulate insulin secretion in the presence of serum albumin. We used this data, together with estimates of free drug concentrations from binding studies, to predict the extent of sulphonylurea inhibition of KATP channels at therapeutic concentrations in vivo. KATP currents from mouse pancreatic β-cells and Xenopus oocytes were measured using the patch-clamp technique. Gliclazide and glibenclamide binding to human plasma were determined in spiked plasma samples using an ultrafiltration-mass spectrometry approach. Bovine serum albumin (60g/l) produced a mild, non-significant reduction of gliclazide block of KATP currents in pancreatic β-cells and Xenopus oocytes. In contrast, glibenclamide inhibition of recombinant KATP channels was dramatically suppressed by albumin (predicted free drug concentration <0.1%). Insulin secretion was also reduced. Free concentrations of gliclazide and glibenclamide in the presence of human plasma measured in binding experiments were 15% and 0.05%, respectively. Our data suggest the free concentration of glibenclamide in plasma is too low to account for the drug's therapeutic effect. In contrast, the free gliclazide concentration in plasma is high enough to close KATP channels and stimulate insulin secretion.http://europepmc.org/articles/PMC5957440?pdf=render
spellingShingle Peter Proks
Holger Kramer
Elizabeth Haythorne
Frances M Ashcroft
Binding of sulphonylureas to plasma proteins - A KATP channel perspective.
PLoS ONE
title Binding of sulphonylureas to plasma proteins - A KATP channel perspective.
title_full Binding of sulphonylureas to plasma proteins - A KATP channel perspective.
title_fullStr Binding of sulphonylureas to plasma proteins - A KATP channel perspective.
title_full_unstemmed Binding of sulphonylureas to plasma proteins - A KATP channel perspective.
title_short Binding of sulphonylureas to plasma proteins - A KATP channel perspective.
title_sort binding of sulphonylureas to plasma proteins a katp channel perspective
url http://europepmc.org/articles/PMC5957440?pdf=render
work_keys_str_mv AT peterproks bindingofsulphonylureastoplasmaproteinsakatpchannelperspective
AT holgerkramer bindingofsulphonylureastoplasmaproteinsakatpchannelperspective
AT elizabethhaythorne bindingofsulphonylureastoplasmaproteinsakatpchannelperspective
AT francesmashcroft bindingofsulphonylureastoplasmaproteinsakatpchannelperspective